Acadian Asset Management
GLMD icon

Acadian Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Acadian Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4
Closed -$57K – 1617
2017
Q3 		$57K Buy
+4
New +$44.3K ﹤0.01% 1089
2016
Q3 		– Sell
-4
Closed -$23K – 1471
2016
Q2 		$23K Hold
4
– – ﹤0.01% 1127
2016
Q1 		$26K Hold
4
– – ﹤0.01% 1105
2015
Q4 		$39K Sell
4
-1
-20% -$12.8K ﹤0.01% 1137
2015
Q3 		$50K Buy
5
+2
+67% +$26.3K ﹤0.01% 1036
2015
Q2 		$38K Buy
+3
New +$41.7K ﹤0.01% 1068

Other funds holding GLMD

6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management's GLMD Position: Q4 2017 in Review

Acadian Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2017, closing a stake of 4 shares — an estimated $57K sold.

Acadian Asset Management first reported a position in GLMD in Q2 2015 and held it in 6 quarters. The position peaked at $57K in Q3 2017. 18 funds tracked by Wall St. Rank hold GLMD as of Q4 2017.

  • Acadian Asset Management reported no remaining Galmed Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Acadian Asset Management sold 4 Galmed Pharmaceuticals shares in Q4 2017, an estimated $57K.
  • Acadian Asset Management first reported a position in Galmed Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Acadian Asset Management's Galmed Pharmaceuticals position peaked at $57K in Q3 2017.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2017.

Based on Acadian Asset Management's 13F filing for Q4 2017, filed 18 Jan 2018.